Loading…
← CockpitCompetitor Analysis › PNV.AX Polynovo LimitedOpen in the cockpit ↗

Polynovo LimitedPNV.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Biotechnology
Momentum laggard 18
Mkt cap
$388M
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$843,286
20-day average traded
Fwd P/E
84.0×
forward earnings
ROIC−WACC
-7.2 pp
WACC 14.1%
Hurdle
+14 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · AUDA$0.84
1D-3.5%
1W-7.2%
1M-7.2%
3M-21.5%
6M-33.9%
YTD-31.7%
1Y-26.6%
ATR %4.1%
52w lowhigh35.2% off high

What Polynovo does

Employees: 301

Polynovo at a glance

Size Polynovo (PNV.AX) is an Australia Health Care company (Biotechnology) with a market value of $388M, the 285th largest of 317 Australia companies the cockpit tracks. Shares closed at A$0.84 on 18 Nov 2026.

Performance Over six months the shares fell 33.9%, against -31.0% for the median peer and +1.2% for the Australia market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 12.9% over the last twelve months (peer median +5.5%); the operating margin is 5.0% (peer median -4.3%).

Valuation It trades at 84.0× forward earnings against a peer median of 16.2× (most expensive of 4).

Price implies For today's price to make sense, revenue must grow about 52% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.2 points below its cost of capital (14.1% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 71PNV.AX 68
Six months, rebased to 100: Polynovo against the median of its 20 peers (local-currency closes).

Polynovo financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$144MA$144MA$127MA$103MA$65.2M
Revenue growth—+13%+23%+58%—
Gross profitA$47.0MA$47.0MA$44.8MA$36.1MA$19.3M
EBITDAA$9.86MA$13.9MA$7.81MA$3.90M-A$3.90M
Net incomeA$7.34MA$7.34MA$13.2MA$5.26M-A$4.92M
Free cash flowA$9.45MA$9.45M-A$10.1MA$2.19M-A$7.46M
Capital expenditureA$13.8MA$13.8MA$13.9MA$2.90MA$1.53M
Total debtn/aA$17.6MA$17.1MA$15.4MA$16.0M

Quarterly statements and history in the cockpit →

Polynovo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-40%-20%0%688687300966ALEC3006832480PRTC688098116730038133786998476060688238EPRX688163CTNM456160CADL476830CRMDPNV.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Polynovo is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×25×50×75×6886871167PNV.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Polynovo is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%+600%0%250%500%750%68868711676998476060PNV.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Polynovo is the large dot.

Polynovo competitors and peer comparison

How Polynovo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Polynovo against its 20 peers (data as of 18 Nov 2026)
MeasurePNV.AXPeer medianRank in peer set
1-month return-7.2%-13.7%8th highest of 21
6-month return-33.9%-31.0%8th lowest of 21
Distance from 52-week high-35.2%-47.6%7th highest of 21
Revenue growth (TTM)+12.9%+5.5%7th highest of 16
Operating margin5.0%-4.3%7th highest of 16
Forward P/E84.0×16.2×most expensive of 4
Growth the price implies (Req g, 7 yrs)51.9%-7.3%most demanding of 5
Growth delivered (Del g)+37.6%+103.1%3rd highest of 5
Hurdle (Req g minus delivered)+14.3 pp-97.6 pp3rd least demanding of 5
ROIC minus cost of capital-7.2 pp-9.2 pp6th highest of 16
EV / EBITDA57.0×5.2×most expensive of 6
Net debt / EBITDA-1.8×-2.6×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Polynovo PNV.AXAustralia$388M-34%+13%5%84.0×51.9%+37.6%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%16.2×36.6%+8.9%
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%n/an/an/a
Alector ALECUnited States$383M+21%+151%25%n/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%n/an/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/a26.2×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%n/an/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%n/an/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%n/an/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%n/a0.6%+725.2%
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%n/an/an/a

Questions

Which companies are Polynovo's closest peers?
The cockpit's peer set: Beijing Kawin Technology Share-Holding (688687.SS), Hubei Goto Biopharm (300966.SZ), Alector (ALEC), Wuhan Hiteck Biological Pharma (300683.SZ), Beijing Luzhu Biotechnology (2480.HK), PureTech Health (PRTC.L), Shanghai Shen Lian Biomedical (688098.SS), Jacobio Pharmaceuticals (1167.HK).
Is Polynovo expensive compared with its peers?
On forward p/e it trades at 84.0× against a peer median of 16.2×, most expensive of 4 in its peer set. For today's price to make sense, revenue must grow about 52% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Polynovo stock performed?
Over six months to 18 Nov 2026 the shares returned -33.9% against -31.0% for the median peer; over one year -26.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.